ParkinsonFranceV1, PascalFrancis, Corpus, bibRecord, 001494

Familial aggregation of Parkinson's disease : A population-based case-control study in Europe

Identifieur interne : 001494 ( PascalFrancis/Corpus ); précédent : 001493; suivant : 001495

Familial aggregation of Parkinson's disease : A population-based case-control study in Europe

Auteurs : A. Elbaz ; F. Grigoletto ; M. Baldereschi ; M. M. Breteler ; J. M. Manubens-Bertran ; S. Lopez-Pousa ; J. F. Dartigues ; A. Alperovitch ; C. Tzourio ; W. A. Rocca

Source :

Neurology [ 0028-3878 ] ; 1999.

RBID : Pascal:99-0340537

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Etude familiale, Epidémiologie, Homme, Incidence, Prévalence, Facteur risque, Europe.

English descriptors

KwdEn :
- Epidemiology, Europe, Family study, Human, Incidence, Parkinson disease, Prevalence, Risk factor.

Abstract

Article abstract-Objective: To investigate the familial aggregation of PD in a large collaborative population-based case-control study. Background: Most previous case-control studies of the familial aggregation of PD have been hospital-or clinic-based. Methods: We included 219 prevalent cases ascertained in three European populations (centers), using a two-phase design consisting of screening and examination by a neurologist. Each case was matched by age, sex, and center to three controls drawn from the same populations (n = 657). Presence of PD among first-degree relatives (parents and siblings) was determined using the family history approach for 175 cases and 481 controls. Results: Overall, a positive family history (at least one parent or sibling affected by PD) was reported in 10.3% of patients and 3.5% of controls (odds ratio [OR] = 3.2; 95% confidence interval [CI] = 1.6 to 6.6). A similar association was observed when analyses were restricted to nondemented patients and controls (OR = 3.9; 95% CI = 1.7 to 8.7) or to newly diagnosed patients (OR = 3.3; 95% CI = 0.9 to 11.9). We found a significant trend of increasing risk with increasing number of affected relatives (p = 0.003). Analyses stratified by age showed a stronger association for younger PD patients (OR = 7.6; 95% CI = 1.5 to 38.9) than for older patients (OR = 2.5; 95% CI = 1.1 to 5.7). Conclusions: In this large sample of prevalent PD patients and population-matched controls, PD significantly aggregates in families, with the strength of the association being age-dependent. Therefore, familial factors, which can be genetic, environmental, or both, play a role in PD.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0028-3878`
A02	`01`			`@0 NEURAI`
A03		`1`		`@0 Neurology`
A05				`@2 52`
A06				`@2 9`
A08	`01`	`1`	`ENG`	`@1 Familial aggregation of Parkinson's disease : A population-based case-control study in Europe`
A11	`01`	`1`		`@1 ELBAZ (A.)`
A11	`02`	`1`		`@1 GRIGOLETTO (F.)`
A11	`03`	`1`		`@1 BALDERESCHI (M.)`
A11	`04`	`1`		`@1 BRETELER (M. M.)`
A11	`05`	`1`		`@1 MANUBENS-BERTRAN (J. M.)`
A11	`06`	`1`		`@1 LOPEZ-POUSA (S.)`
A11	`07`	`1`		`@1 DARTIGUES (J. F.)`
A11	`08`	`1`		`@1 ALPEROVITCH (A.)`
A11	`09`	`1`		`@1 TZOURIO (C.)`
A11	`10`	`1`		`@1 ROCCA (W. A.)`
A14	`01`			`@1 INSERM U 360, Recherches Epidémiologiques en Neurologie et Psychopathologie, Hôpital de la Salpêtrière @2 Paris @3 FRA @Z 1 aut. @Z 8 aut. @Z 9 aut.`
A14	`02`			`@1 Institute of Hygiene, University of Padua @2 Padova @3 ITA @Z 2 aut.`
A14	`03`			`@1 Targeted Project on Aging, National Research Council @2 Florence @3 ITA @Z 3 aut.`
A14	`04`			`@1 Department of Epidemiology and Biostatistics, Erasmus University Medical School @2 Rotterdam @3 NLD @Z 4 aut.`
A14	`05`			`@1 Department of Neurology, University of Navarra @2 Pamplona @3 ESP @Z 5 aut.`
A14	`06`			`@1 Department of Neurology, University Hospital Sta. Caterina @2 Girona @3 ESP @Z 6 aut.`
A14	`07`			`@1 Department of Neurology, Pellegrin Hospital, University of Bordeaux II @3 FRA @Z 7 aut.`
A14	`08`			`@1 Departments of Health Sciences Research and Neurology, Mayo Clinic and Mayo Foundation @2 Rochester, MN @3 USA @Z 10 aut.`
A17	`01`	`1`		`@1 EUROPARKINSON Study Group @3 EUR`
A20				`@1 1876-1882`
A21				`@1 1999`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 6345 @5 354000085281510250`
A44				`@0 0000 @1 © 1999 INIST-CNRS. All rights reserved.`
A45				`@0 38 ref.`
A47	`01`	`1`		`@0 99-0340537`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Neurology`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Article abstract-Objective: To investigate the familial aggregation of PD in a large collaborative population-based case-control study. Background: Most previous case-control studies of the familial aggregation of PD have been hospital-or clinic-based. Methods: We included 219 prevalent cases ascertained in three European populations (centers), using a two-phase design consisting of screening and examination by a neurologist. Each case was matched by age, sex, and center to three controls drawn from the same populations (n = 657). Presence of PD among first-degree relatives (parents and siblings) was determined using the family history approach for 175 cases and 481 controls. Results: Overall, a positive family history (at least one parent or sibling affected by PD) was reported in 10.3% of patients and 3.5% of controls (odds ratio [OR] = 3.2; 95% confidence interval [CI] = 1.6 to 6.6). A similar association was observed when analyses were restricted to nondemented patients and controls (OR = 3.9; 95% CI = 1.7 to 8.7) or to newly diagnosed patients (OR = 3.3; 95% CI = 0.9 to 11.9). We found a significant trend of increasing risk with increasing number of affected relatives (p = 0.003). Analyses stratified by age showed a stronger association for younger PD patients (OR = 7.6; 95% CI = 1.5 to 38.9) than for older patients (OR = 2.5; 95% CI = 1.1 to 5.7). Conclusions: In this large sample of prevalent PD patients and population-matched controls, PD significantly aggregates in families, with the strength of the association being age-dependent. Therefore, familial factors, which can be genetic, environmental, or both, play a role in PD.
C02	`01`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Etude familiale @5 16`
C03	`02`	`X`	`ENG`	`@0 Family study @5 16`
C03	`02`	`X`	`SPA`	`@0 Estudio familiar @5 16`
C03	`03`	`X`	`FRE`	`@0 Epidémiologie @5 17`
C03	`03`	`X`	`ENG`	`@0 Epidemiology @5 17`
C03	`03`	`X`	`SPA`	`@0 Epidemiología @5 17`
C03	`04`	`X`	`FRE`	`@0 Homme @5 20`
C03	`04`	`X`	`ENG`	`@0 Human @5 20`
C03	`04`	`X`	`SPA`	`@0 Hombre @5 20`
C03	`05`	`X`	`FRE`	`@0 Incidence @5 23`
C03	`05`	`X`	`ENG`	`@0 Incidence @5 23`
C03	`05`	`X`	`SPA`	`@0 Incidencia @5 23`
C03	`06`	`X`	`FRE`	`@0 Prévalence @5 24`
C03	`06`	`X`	`ENG`	`@0 Prevalence @5 24`
C03	`06`	`X`	`SPA`	`@0 Prevalencia @5 24`
C03	`07`	`X`	`FRE`	`@0 Facteur risque @5 35`
C03	`07`	`X`	`ENG`	`@0 Risk factor @5 35`
C03	`07`	`X`	`SPA`	`@0 Factor riesgo @5 35`
C03	`08`	`X`	`FRE`	`@0 Europe @2 NG @5 36`
C03	`08`	`X`	`ENG`	`@0 Europe @2 NG @5 36`
C03	`08`	`X`	`SPA`	`@0 Europa @2 NG @5 36`
C07	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`02`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`03`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`03`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`04`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`05`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
N21				`@1 214`

Format Inist (serveur)

NO :	PASCAL 99-0340537 INIST
ET :	Familial aggregation of Parkinson's disease : A population-based case-control study in Europe
AU :	ELBAZ (A.); GRIGOLETTO (F.); BALDERESCHI (M.); BRETELER (M. M.); MANUBENS-BERTRAN (J. M.); LOPEZ-POUSA (S.); DARTIGUES (J. F.); ALPEROVITCH (A.); TZOURIO (C.); ROCCA (W. A.)
AF :	INSERM U 360, Recherches Epidémiologiques en Neurologie et Psychopathologie, Hôpital de la Salpêtrière/Paris/France (1 aut., 8 aut., 9 aut.); Institute of Hygiene, University of Padua/Padova/Italie (2 aut.); Targeted Project on Aging, National Research Council/Florence/Italie (3 aut.); Department of Epidemiology and Biostatistics, Erasmus University Medical School/Rotterdam/Pays-Bas (4 aut.); Department of Neurology, University of Navarra/Pamplona/Espagne (5 aut.); Department of Neurology, University Hospital Sta. Caterina/Girona/Espagne (6 aut.); Department of Neurology, Pellegrin Hospital, University of Bordeaux II/France (7 aut.); Departments of Health Sciences Research and Neurology, Mayo Clinic and Mayo Foundation/Rochester, MN/Etats-Unis (10 aut.)
DT :	Publication en série; Niveau analytique
SO :	Neurology; ISSN 0028-3878; Coden NEURAI; Etats-Unis; Da. 1999; Vol. 52; No. 9; Pp. 1876-1882; Bibl. 38 ref.
LA :	Anglais
EA :	Article abstract-Objective: To investigate the familial aggregation of PD in a large collaborative population-based case-control study. Background: Most previous case-control studies of the familial aggregation of PD have been hospital-or clinic-based. Methods: We included 219 prevalent cases ascertained in three European populations (centers), using a two-phase design consisting of screening and examination by a neurologist. Each case was matched by age, sex, and center to three controls drawn from the same populations (n = 657). Presence of PD among first-degree relatives (parents and siblings) was determined using the family history approach for 175 cases and 481 controls. Results: Overall, a positive family history (at least one parent or sibling affected by PD) was reported in 10.3% of patients and 3.5% of controls (odds ratio [OR] = 3.2; 95% confidence interval [CI] = 1.6 to 6.6). A similar association was observed when analyses were restricted to nondemented patients and controls (OR = 3.9; 95% CI = 1.7 to 8.7) or to newly diagnosed patients (OR = 3.3; 95% CI = 0.9 to 11.9). We found a significant trend of increasing risk with increasing number of affected relatives (p = 0.003). Analyses stratified by age showed a stronger association for younger PD patients (OR = 7.6; 95% CI = 1.5 to 38.9) than for older patients (OR = 2.5; 95% CI = 1.1 to 5.7). Conclusions: In this large sample of prevalent PD patients and population-matched controls, PD significantly aggregates in families, with the strength of the association being age-dependent. Therefore, familial factors, which can be genetic, environmental, or both, play a role in PD.
CC :	002B17G
FD :	Parkinson maladie; Etude familiale; Epidémiologie; Homme; Incidence; Prévalence; Facteur risque; Europe
FG :	Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative
ED :	Parkinson disease; Family study; Epidemiology; Human; Incidence; Prevalence; Risk factor; Europe
EG :	Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease
SD :	Parkinson enfermedad; Estudio familiar; Epidemiología; Hombre; Incidencia; Prevalencia; Factor riesgo; Europa
LO :	INIST-6345.354000085281510250
ID :	99-0340537

Links to Exploration step

Pascal:99-0340537

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Familial aggregation of Parkinson's disease : A population-based case-control study in Europe</title>
<author><name sortKey="Elbaz, A" sort="Elbaz, A" uniqKey="Elbaz A" first="A." last="Elbaz">A. Elbaz</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM U 360, Recherches Epidémiologiques en Neurologie et Psychopathologie, Hôpital de la Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Grigoletto, F" sort="Grigoletto, F" uniqKey="Grigoletto F" first="F." last="Grigoletto">F. Grigoletto</name>
<affiliation><inist:fA14 i1="02"><s1>Institute of Hygiene, University of Padua</s1>
<s2>Padova</s2>
<s3>ITA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Baldereschi, M" sort="Baldereschi, M" uniqKey="Baldereschi M" first="M." last="Baldereschi">M. Baldereschi</name>
<affiliation><inist:fA14 i1="03"><s1>Targeted Project on Aging, National Research Council</s1>
<s2>Florence</s2>
<s3>ITA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Breteler, M M" sort="Breteler, M M" uniqKey="Breteler M" first="M. M." last="Breteler">M. M. Breteler</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Epidemiology and Biostatistics, Erasmus University Medical School</s1>
<s2>Rotterdam</s2>
<s3>NLD</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Manubens Bertran, J M" sort="Manubens Bertran, J M" uniqKey="Manubens Bertran J" first="J. M." last="Manubens-Bertran">J. M. Manubens-Bertran</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Neurology, University of Navarra</s1>
<s2>Pamplona</s2>
<s3>ESP</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lopez Pousa, S" sort="Lopez Pousa, S" uniqKey="Lopez Pousa S" first="S." last="Lopez-Pousa">S. Lopez-Pousa</name>
<affiliation><inist:fA14 i1="06"><s1>Department of Neurology, University Hospital Sta. Caterina</s1>
<s2>Girona</s2>
<s3>ESP</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dartigues, J F" sort="Dartigues, J F" uniqKey="Dartigues J" first="J. F." last="Dartigues">J. F. Dartigues</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Neurology, Pellegrin Hospital, University of Bordeaux II</s1>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Alperovitch, A" sort="Alperovitch, A" uniqKey="Alperovitch A" first="A." last="Alperovitch">A. Alperovitch</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM U 360, Recherches Epidémiologiques en Neurologie et Psychopathologie, Hôpital de la Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tzourio, C" sort="Tzourio, C" uniqKey="Tzourio C" first="C." last="Tzourio">C. Tzourio</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM U 360, Recherches Epidémiologiques en Neurologie et Psychopathologie, Hôpital de la Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rocca, W A" sort="Rocca, W A" uniqKey="Rocca W" first="W. A." last="Rocca">W. A. Rocca</name>
<affiliation><inist:fA14 i1="08"><s1>Departments of Health Sciences Research and Neurology, Mayo Clinic and Mayo Foundation</s1>
<s2>Rochester, MN</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">99-0340537</idno>
<date when="1999">1999</date>
<idno type="stanalyst">PASCAL 99-0340537 INIST</idno>
<idno type="RBID">Pascal:99-0340537</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001494</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Familial aggregation of Parkinson's disease : A population-based case-control study in Europe</title>
<author><name sortKey="Elbaz, A" sort="Elbaz, A" uniqKey="Elbaz A" first="A." last="Elbaz">A. Elbaz</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM U 360, Recherches Epidémiologiques en Neurologie et Psychopathologie, Hôpital de la Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Grigoletto, F" sort="Grigoletto, F" uniqKey="Grigoletto F" first="F." last="Grigoletto">F. Grigoletto</name>
<affiliation><inist:fA14 i1="02"><s1>Institute of Hygiene, University of Padua</s1>
<s2>Padova</s2>
<s3>ITA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Baldereschi, M" sort="Baldereschi, M" uniqKey="Baldereschi M" first="M." last="Baldereschi">M. Baldereschi</name>
<affiliation><inist:fA14 i1="03"><s1>Targeted Project on Aging, National Research Council</s1>
<s2>Florence</s2>
<s3>ITA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Breteler, M M" sort="Breteler, M M" uniqKey="Breteler M" first="M. M." last="Breteler">M. M. Breteler</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Epidemiology and Biostatistics, Erasmus University Medical School</s1>
<s2>Rotterdam</s2>
<s3>NLD</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Manubens Bertran, J M" sort="Manubens Bertran, J M" uniqKey="Manubens Bertran J" first="J. M." last="Manubens-Bertran">J. M. Manubens-Bertran</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Neurology, University of Navarra</s1>
<s2>Pamplona</s2>
<s3>ESP</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lopez Pousa, S" sort="Lopez Pousa, S" uniqKey="Lopez Pousa S" first="S." last="Lopez-Pousa">S. Lopez-Pousa</name>
<affiliation><inist:fA14 i1="06"><s1>Department of Neurology, University Hospital Sta. Caterina</s1>
<s2>Girona</s2>
<s3>ESP</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dartigues, J F" sort="Dartigues, J F" uniqKey="Dartigues J" first="J. F." last="Dartigues">J. F. Dartigues</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Neurology, Pellegrin Hospital, University of Bordeaux II</s1>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Alperovitch, A" sort="Alperovitch, A" uniqKey="Alperovitch A" first="A." last="Alperovitch">A. Alperovitch</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM U 360, Recherches Epidémiologiques en Neurologie et Psychopathologie, Hôpital de la Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tzourio, C" sort="Tzourio, C" uniqKey="Tzourio C" first="C." last="Tzourio">C. Tzourio</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM U 360, Recherches Epidémiologiques en Neurologie et Psychopathologie, Hôpital de la Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rocca, W A" sort="Rocca, W A" uniqKey="Rocca W" first="W. A." last="Rocca">W. A. Rocca</name>
<affiliation><inist:fA14 i1="08"><s1>Departments of Health Sciences Research and Neurology, Mayo Clinic and Mayo Foundation</s1>
<s2>Rochester, MN</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Neurology</title>
<title level="j" type="abbreviated">Neurology</title>
<idno type="ISSN">0028-3878</idno>
<imprint><date when="1999">1999</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Neurology</title>
<title level="j" type="abbreviated">Neurology</title>
<idno type="ISSN">0028-3878</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Epidemiology</term>
<term>Europe</term>
<term>Family study</term>
<term>Human</term>
<term>Incidence</term>
<term>Parkinson disease</term>
<term>Prevalence</term>
<term>Risk factor</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Etude familiale</term>
<term>Epidémiologie</term>
<term>Homme</term>
<term>Incidence</term>
<term>Prévalence</term>
<term>Facteur risque</term>
<term>Europe</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Article abstract-Objective: To investigate the familial aggregation of PD in a large collaborative population-based case-control study. Background: Most previous case-control studies of the familial aggregation of PD have been hospital-or clinic-based. Methods: We included 219 prevalent cases ascertained in three European populations (centers), using a two-phase design consisting of screening and examination by a neurologist. Each case was matched by age, sex, and center to three controls drawn from the same populations (n = 657). Presence of PD among first-degree relatives (parents and siblings) was determined using the family history approach for 175 cases and 481 controls. Results: Overall, a positive family history (at least one parent or sibling affected by PD) was reported in 10.3% of patients and 3.5% of controls (odds ratio [OR] = 3.2; 95% confidence interval [CI] = 1.6 to 6.6). A similar association was observed when analyses were restricted to nondemented patients and controls (OR = 3.9; 95% CI = 1.7 to 8.7) or to newly diagnosed patients (OR = 3.3; 95% CI = 0.9 to 11.9). We found a significant trend of increasing risk with increasing number of affected relatives (p = 0.003). Analyses stratified by age showed a stronger association for younger PD patients (OR = 7.6; 95% CI = 1.5 to 38.9) than for older patients (OR = 2.5; 95% CI = 1.1 to 5.7). Conclusions: In this large sample of prevalent PD patients and population-matched controls, PD significantly aggregates in families, with the strength of the association being age-dependent. Therefore, familial factors, which can be genetic, environmental, or both, play a role in PD.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0028-3878</s0>
</fA01>
<fA02 i1="01"><s0>NEURAI</s0>
</fA02>
<fA03 i2="1"><s0>Neurology</s0>
</fA03>
<fA05><s2>52</s2>
</fA05>
<fA06><s2>9</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Familial aggregation of Parkinson's disease : A population-based case-control study in Europe</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>ELBAZ (A.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>GRIGOLETTO (F.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>BALDERESCHI (M.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>BRETELER (M. M.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>MANUBENS-BERTRAN (J. M.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>LOPEZ-POUSA (S.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>DARTIGUES (J. F.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>ALPEROVITCH (A.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>TZOURIO (C.)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>ROCCA (W. A.)</s1>
</fA11>
<fA14 i1="01"><s1>INSERM U 360, Recherches Epidémiologiques en Neurologie et Psychopathologie, Hôpital de la Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Institute of Hygiene, University of Padua</s1>
<s2>Padova</s2>
<s3>ITA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Targeted Project on Aging, National Research Council</s1>
<s2>Florence</s2>
<s3>ITA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Epidemiology and Biostatistics, Erasmus University Medical School</s1>
<s2>Rotterdam</s2>
<s3>NLD</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Neurology, University of Navarra</s1>
<s2>Pamplona</s2>
<s3>ESP</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Department of Neurology, University Hospital Sta. Caterina</s1>
<s2>Girona</s2>
<s3>ESP</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Department of Neurology, Pellegrin Hospital, University of Bordeaux II</s1>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Departments of Health Sciences Research and Neurology, Mayo Clinic and Mayo Foundation</s1>
<s2>Rochester, MN</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA17 i1="01" i2="1"><s1>EUROPARKINSON Study Group</s1>
<s3>EUR</s3>
</fA17>
<fA20><s1>1876-1882</s1>
</fA20>
<fA21><s1>1999</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>6345</s2>
<s5>354000085281510250</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 1999 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>38 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>99-0340537</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Neurology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Article abstract-Objective: To investigate the familial aggregation of PD in a large collaborative population-based case-control study. Background: Most previous case-control studies of the familial aggregation of PD have been hospital-or clinic-based. Methods: We included 219 prevalent cases ascertained in three European populations (centers), using a two-phase design consisting of screening and examination by a neurologist. Each case was matched by age, sex, and center to three controls drawn from the same populations (n = 657). Presence of PD among first-degree relatives (parents and siblings) was determined using the family history approach for 175 cases and 481 controls. Results: Overall, a positive family history (at least one parent or sibling affected by PD) was reported in 10.3% of patients and 3.5% of controls (odds ratio [OR] = 3.2; 95% confidence interval [CI] = 1.6 to 6.6). A similar association was observed when analyses were restricted to nondemented patients and controls (OR = 3.9; 95% CI = 1.7 to 8.7) or to newly diagnosed patients (OR = 3.3; 95% CI = 0.9 to 11.9). We found a significant trend of increasing risk with increasing number of affected relatives (p = 0.003). Analyses stratified by age showed a stronger association for younger PD patients (OR = 7.6; 95% CI = 1.5 to 38.9) than for older patients (OR = 2.5; 95% CI = 1.1 to 5.7). Conclusions: In this large sample of prevalent PD patients and population-matched controls, PD significantly aggregates in families, with the strength of the association being age-dependent. Therefore, familial factors, which can be genetic, environmental, or both, play a role in PD.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Etude familiale</s0>
<s5>16</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Family study</s0>
<s5>16</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Estudio familiar</s0>
<s5>16</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Epidémiologie</s0>
<s5>17</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Epidemiology</s0>
<s5>17</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Epidemiología</s0>
<s5>17</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Incidence</s0>
<s5>23</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Incidence</s0>
<s5>23</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Incidencia</s0>
<s5>23</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Prévalence</s0>
<s5>24</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Prevalence</s0>
<s5>24</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Prevalencia</s0>
<s5>24</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Facteur risque</s0>
<s5>35</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Risk factor</s0>
<s5>35</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Factor riesgo</s0>
<s5>35</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Europe</s0>
<s2>NG</s2>
<s5>36</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Europe</s0>
<s2>NG</s2>
<s5>36</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Europa</s0>
<s2>NG</s2>
<s5>36</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fN21><s1>214</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 99-0340537 INIST</NO>
<ET>Familial aggregation of Parkinson's disease : A population-based case-control study in Europe</ET>
<AU>ELBAZ (A.); GRIGOLETTO (F.); BALDERESCHI (M.); BRETELER (M. M.); MANUBENS-BERTRAN (J. M.); LOPEZ-POUSA (S.); DARTIGUES (J. F.); ALPEROVITCH (A.); TZOURIO (C.); ROCCA (W. A.)</AU>
<AF>INSERM U 360, Recherches Epidémiologiques en Neurologie et Psychopathologie, Hôpital de la Salpêtrière/Paris/France (1 aut., 8 aut., 9 aut.); Institute of Hygiene, University of Padua/Padova/Italie (2 aut.); Targeted Project on Aging, National Research Council/Florence/Italie (3 aut.); Department of Epidemiology and Biostatistics, Erasmus University Medical School/Rotterdam/Pays-Bas (4 aut.); Department of Neurology, University of Navarra/Pamplona/Espagne (5 aut.); Department of Neurology, University Hospital Sta. Caterina/Girona/Espagne (6 aut.); Department of Neurology, Pellegrin Hospital, University of Bordeaux II/France (7 aut.); Departments of Health Sciences Research and Neurology, Mayo Clinic and Mayo Foundation/Rochester, MN/Etats-Unis (10 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Neurology; ISSN 0028-3878; Coden NEURAI; Etats-Unis; Da. 1999; Vol. 52; No. 9; Pp. 1876-1882; Bibl. 38 ref.</SO>
<LA>Anglais</LA>
<EA>Article abstract-Objective: To investigate the familial aggregation of PD in a large collaborative population-based case-control study. Background: Most previous case-control studies of the familial aggregation of PD have been hospital-or clinic-based. Methods: We included 219 prevalent cases ascertained in three European populations (centers), using a two-phase design consisting of screening and examination by a neurologist. Each case was matched by age, sex, and center to three controls drawn from the same populations (n = 657). Presence of PD among first-degree relatives (parents and siblings) was determined using the family history approach for 175 cases and 481 controls. Results: Overall, a positive family history (at least one parent or sibling affected by PD) was reported in 10.3% of patients and 3.5% of controls (odds ratio [OR] = 3.2; 95% confidence interval [CI] = 1.6 to 6.6). A similar association was observed when analyses were restricted to nondemented patients and controls (OR = 3.9; 95% CI = 1.7 to 8.7) or to newly diagnosed patients (OR = 3.3; 95% CI = 0.9 to 11.9). We found a significant trend of increasing risk with increasing number of affected relatives (p = 0.003). Analyses stratified by age showed a stronger association for younger PD patients (OR = 7.6; 95% CI = 1.5 to 38.9) than for older patients (OR = 2.5; 95% CI = 1.1 to 5.7). Conclusions: In this large sample of prevalent PD patients and population-matched controls, PD significantly aggregates in families, with the strength of the association being age-dependent. Therefore, familial factors, which can be genetic, environmental, or both, play a role in PD.</EA>
<CC>002B17G</CC>
<FD>Parkinson maladie; Etude familiale; Epidémiologie; Homme; Incidence; Prévalence; Facteur risque; Europe</FD>
<FG>Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative</FG>
<ED>Parkinson disease; Family study; Epidemiology; Human; Incidence; Prevalence; Risk factor; Europe</ED>
<EG>Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease</EG>
<SD>Parkinson enfermedad; Estudio familiar; Epidemiología; Hombre; Incidencia; Prevalencia; Factor riesgo; Europa</SD>
<LO>INIST-6345.354000085281510250</LO>
<ID>99-0340537</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001494 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001494 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:99-0340537
   |texte=   Familial aggregation of Parkinson's disease : A population-based case-control study in Europe
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Familial aggregation of Parkinson's disease : A population-based case-control study in Europe

Familial aggregation of Parkinson's disease : A population-based case-control study in Europe

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri